Published in Medical Letter on the CDC and FDA, September 13th, 2009
"For tigecycline, we used the criteria approved by the FDA. Almost 50% of the clinical isolates of Acinetobacter spp. were resistant to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.